Didier Véron
Pharmaceutical Sciences
IPSEN Biologics
Ireland
Biography
Didier Véron has served as Senior Vice-President, Public Affairs and Corporate Communication since 2013. After beginning his career at the National Federation of Public Works, Didier Véron gained over 20 years of experience in the healthcare sector; firstly at the French Medicines Agency working with the CEO, and then joining the pharmaceutical industry as a special advisor to the General Management of Ipsen. Didier now holds the position of Senior Vice President, Public Affairs and Corporate Communication at Ipsen. Didier is a member of the Board of Directors of Leem, the French Trade Association of Pharmaceutical Industries. Didier chairs the Public Affairs France / Europe Committee. He is also Secretary of the Strategic Committee of Healthcare Industries and Technologies. He is a lecturer at the Institut d’Etudes Politiques de Paris (Sciences Po Paris). Didier is a graduate of Sciences Po Paris and has a post-graduate degree in Health Law from Southern Paris University. Close Didier Véron has served as Senior Vice-President, Public Affairs and Corporate Communication since 2013. After beginning his career at the National Federation of Public Works, Didier Véron gained over 20 years of experience in the healthcare sector; firstly at the French Medicines Agency working with the CEO, and then joining the pharmaceutical industry as a special advisor to the General Management of Ipsen. Didier now holds the position of Senior Vice President, Public Affairs and Corporate Communication at Ipsen. Didier is a member of the Board of Directors of Leem, the French Trade Association of Pharmaceutical Industries. Didier chairs the Public Affairs France / Europe Committee. He is also Secretary of the Strategic Committee of Healthcare Industries and Technologies. He is a lecturer at the Institut d’Etudes Politiques de Paris (Sciences Po Paris). Didier is a graduate of Sciences Po Paris and has a post-graduate degree in Health Law from Southern Paris University. Close
Research Interest
Pharmaceuticals
